A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Sep 2018
At a glance
- Drugs Ublituximab (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms GENUINE
- Sponsors TG Therapeutics Inc
- 12 Sep 2018 Planned End Date changed from 1 Aug 2018 to 1 Nov 2019.
- 12 Sep 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 11 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History